Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Beckman Research Institute National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00712634 |
RATIONALE: Vaccines may help the body build an effective immune response against cytomegalovirus.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of cytomegalovirus vaccine in healthy participants.
Condition | Intervention | Phase |
---|---|---|
Precancerous/Nonmalignant Condition |
Biological: CMVpp65-A*0201 peptide vaccine |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control |
Official Title: | A Phase I Dose Escalation Study of Lipopeptide Vaccines With Activity Against Human Cytomegalovirus |
Estimated Enrollment: | 46 |
Study Start Date: | November 1997 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
CMV-seropositive participants: Experimental
Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
|
Biological: CMVpp65-A*0201 peptide vaccine
Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
|
CMV-seronegative participants: Experimental
Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
|
Biological: CMVpp65-A*0201 peptide vaccine
Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
|
OBJECTIVES:
OUTLINE: This is a dose-escalation study of CMVpp65-A*0201 peptide vaccine in cytomegalovirus (CMV)-seropositive participants. Once a safe dose is established, CMV-seronegative participants are accrued and immunized at that dose. Participants are stratified according to gender.
After completion of study therapy, participants are followed for 12 months.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
No concurrent daily medications for chronic or current illness, except for the following:
United States, California | |
City of Hope Comprehensive Cancer Center | |
Duarte, California, United States, 91010-3000 |
Principal Investigator: | Don Diamond, PhD | Beckman Research Institute |
Responsible Party: | City of Hope Comprehensive Cancer Center ( Don Diamond ) |
Study ID Numbers: | CDR0000599675, CHNMC-97092 |
Study First Received: | July 9, 2008 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00712634 History of Changes |
Health Authority: | United States: Federal Government |
cytomegalovirus infection |
Virus Diseases Precancerous Conditions Cytomegalic Inclusion Disease Cytomegalovirus Infections |
DNA Virus Infections Healthy Cytomegalovirus Herpesviridae Infections |
Virus Diseases Neoplasms Precancerous Conditions |
Cytomegalovirus Infections DNA Virus Infections Herpesviridae Infections |